<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197808</url>
  </required_header>
  <id_info>
    <org_study_id>sched1</org_study_id>
    <nct_id>NCT00197808</nct_id>
  </id_info>
  <brief_title>Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines</brief_title>
  <acronym>sched1</acronym>
  <official_title>Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health England</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Public Health England</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the immune responses of UK infants after one or two
      doses of pneumococcal conjugate vaccine or one or two doses of three different types of
      meningococcal conjugate vaccine given at either two and three or two and four months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>3 months after last sample</time_frame>
    <description>SBA men C responses</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Pneumococcal Infections</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Vaccine schedule 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Menjugate vaccine at 2 and 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine schedule 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Menjugate vaccine at 2 and 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine schedule3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neissvacc at 2 and 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine schedule 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neissvacc at 2 and 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine schedule 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meningitec at 2 and 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine schedule 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meningitec at 2 and 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>menjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>Vaccine schedule 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C conjugate vaccine</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>Vaccine schedule 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C conjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>vaccine schedule3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C Conjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>vaccine schedule 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C conjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>Vaccine schedule 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Men C conjugate</intervention_name>
    <description>men C conjugate vaccine</description>
    <arm_group_label>Vaccine schedule 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from parent or legal guardian of infant

          -  Age 7-11 weeks at first dose

        Exclusion Criteria:

          -  Any contraindications to vaccination as specified in the UK Handbook &quot;Immunisation
             Against Infectious Disease&quot; (Ed 1996)

          -  &lt; 7 weeks or &gt; 11 weeks at first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Weeks</minimum_age>
    <maximum_age>11 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Miller, MBBS, FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Public Health England</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hertfordshire Primary Care Trusts</name>
      <address>
        <city>Welwyn Garden City</city>
        <state>Hertfordshire</state>
        <zip>AL8 6JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Primary Care Trusts</name>
      <address>
        <city>Gloucester</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 27, 2012</last_update_submitted>
  <last_update_submitted_qc>March 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Public Health England</investigator_affiliation>
    <investigator_full_name>Dr. Elizabeth Miller</investigator_full_name>
    <investigator_title>Consultant epidemiologist</investigator_title>
  </responsible_party>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

